Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564046 | 1.00 | CHRM1 (0.48) | CHRM1HRH1PAK1DRD2DRD1 | |
| SCHEMBL5564042 | 1.00 | CHRM1 (0.48) | CHRM1HRH1PAK1DRD2DRD1 | |
| Succinic Acid SCHEMBL5563925 | 0.94 | CHRM1 (0.42) | CHRM1HRH1PAK1 | |
| Succinic Acid SCHEMBL5563931 | 0.94 | CHRM1 (0.42) | CHRM1HRH1PAK1 | |
| SCHEMBL14156677 | 0.91 | CHRM1 (0.49) | CHRM1HRH1PAK1 | |
| SCHEMBL4846426 | 0.89 | CHRM1 (0.47) | CHRM1HRH1PAK1DRD2DRD1 | |
| SCHEMBL4846434 | 0.89 | CHRM1 (0.47) | CHRM1HRH1PAK1DRD2DRD1 | |
| SCHEMBL4846422 | 0.89 | CHRM1 (0.47) | CHRM1HRH1PAK1DRD2DRD1 | |
| SCHEMBL5559491 | 0.89 | CHRM1 (0.50) | CHRM1HRH1PAK1DRD2DRD1 | |
| SCHEMBL5559499 | 0.89 | CHRM1 (0.50) | CHRM1HRH1PAK1DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492794-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | LILLY CO ELI (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1492794-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | LILLY CO ELI (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7214673-B2 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214673-B2 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214673-B2 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | DRD4, AFF4, DRD2 | CHRM1 203/4885HRH1 201/4885PAK1 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.